Targeting Tumorangiogenesis in Lung Cancer by Suppression of VEGF and its Receptor - Results from Clinical Trials and Novel Experimental Approaches

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|14|30|3157-3165

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.14, Iss.30, 2007-12, pp. : 3157-3165

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting VEGF in lung cancer

By Das Millie   Wakelee Heather  

Expert Opinion on Therapeutic Targets, Vol. 16, Iss. 4, 2012-04 ,pp. : 395-406

Informa Healthcare

Access to resources Recommend Favorite

Challenges in Lung Cancer Approaches: from the Clinical Issues to the Novel Therapies

By  

Recent Advances in DNA & Gene Sequences (Formerly Recent Patents on DNA & Gene Sequences), Vol. 9, Iss. 1, 2015-04 ,pp. : 45-50

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical trials report on ongoing trials in lung cancer

By Giaccone G.   van Meerbeck J.  

Expert Opinion on Investigational Drugs, Vol. 6, Iss. 12, 1997-12 ,pp. : 1939-1950

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic targeting of receptor tyrosine kinases in lung cancer

By Choong Nicholas W   Ma Patrick C   Salgia Ravi  

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 3, 2005-06 ,pp. : 533-559

Informa Healthcare

Access to resources Recommend Favorite

Novel VEGF-independent Strategies Targeting Tumor Vasculature: Clinical Aspects

By  

Current Pharmaceutical Design, Vol. 18, Iss. 19, 2012-06 ,pp. : 2702-2712

Bentham Science Publishers

Access to resources Recommend Favorite